Regarding the expression of CD133, we found that the mean survival time of HCC patients in the low expression group was 68.42 ± 3.55 months, compared with 54.36 ± 5.30 months in the high expression group. This evidence concerns the gene PROM1 and hepatocellular carcinoma.